Acalabrutinib in Patients (pts) with Waldenstrom Macroglobulinemia (WM)
Publication date
2018-09
Authors
Owen, Roger
McCarthy, Helen
Rule, Simon
D'Sa, Shirley
Thomas, Sheeba
Forconi, Francesco
Anderson, Thomas
Kersten, Marie Jose
Zinzani, Pier Luigi
Iyengar, Sunil
Editors
Advisors
Supervisors
DOI
Document Type
Abstract
Metadata
Show full item recordCollections
License
taverne
Abstract
Keywords
Waldenström macroglobulinemia, acalabrutinib, relapsed, refractory, treatment-naïve, BTK inhibitor, Taverne
Citation
Owen, R, McCarthy, H, Rule, S, D'Sa, S, Thomas, S, Forconi, F, Anderson, T, Kersten, M J, Zinzani, P L, Iyengar, S, Kothari, J, Minnema, M, Kastritis, E, Izumi, R, Slatter, J G, Mittag, D, Wei, H, Chen, D-Y, Patel, P & Furman, R R 2018, 'Acalabrutinib in Patients (pts) with Waldenstrom Macroglobulinemia (WM)', Clinical Lymphoma, Myeloma and Leukemia, vol. 18, pp. S285-S286.